Erfo Pharmaceutical Laboratory

What Erfo Pharmaceutical Laboratory does

Erfo Pharmaceutical Laboratory S.p.A. (Laboratorio Farmaceutico Erfo) is an Italian nutraceutical manufacturer and multi-brand wellness franchisor founded in 2013 by Alessandro Cutè and headquartered in Villafranca Tirrena (ME), Sicily. Listed on Euronext Growth Milan since June 2022 (ticker ERFO, ISIN IT0005497885), the company operates a vertically integrated Health & Wellness ecosystem combining in-house research, ISO 9001:2015-certified and Industry 4.0-compliant manufacturing, and a 274-point franchise network across Italy, France, and Belgium under three proprietary retail brands: Diétnatural (nutrition and wellness, 120+ points), Fit&Go (high-tech fitness, 120+ points, acquired February 2025), and BodySano (nutrition and aesthetics for francophone markets, acquired January 2023). FY2025 consolidated revenue reached approximately €10 million (+61% YoY).

The company produces 70+ proprietary nutraceutical SKUs from a Villafranca facility capable of 200,000+ tablets annually, including the Erfo Medical Division portfolio of therapeutically-oriented supplements (Osteo-Therapy®, Osteo-Protex, Blue Performa, Alginat Plus, Butiplus Repair, Effervia, Glusan Epato Detox, Lattasi Pro, Prebiolians Immunoact, Procinetix Digestion, Transax Regolarità, FerroPro Forte, Policistix Myo-Chiro, Mind 1000, Neuro-Therapy Brain, Trianase Plus, Emorvia, Plusven Forte) spanning andrology, gastroenterology, gynecology, neurology, dentistry, orthopedics, and vascular health, distributed through pharmacies and healthcare professionals. R&D activity is anchored by two multi-partner projects—PLATFORM (orthopedic regenerative medicine, with a polyphenol-based bone regeneration patent filed December 2024) with C.O.T., Università Campus Bio-Medico di Roma, AMED, and NCS Lab, and PLANTS (smart greenhouse cultivation of medicinal plants with CNR)—and the company holds two registered trademarks (OSTEO-THERAPY®, POLICISTIX).

Erfo's revenue model combines branded nutraceutical product sales (via the franchise network and direct-to-consumer Erfo Shop e-commerce platform launched October 2025), private label and contract manufacturing services ("Conto Terzi" with 80+ client formulations developed), franchise setup and royalty fees across 274 sales points, and Medical Division sales through pharmacy and clinical channels. The Medical Division was spun out in July 2025 as Erfo Pharma to scale therapeutic-channel distribution. Controlling shareholder Active Capital Investment S.p.A. holds 61.40% of capital (65.19% of voting rights), with a public float of approximately 32.79% on Euronext Growth Milan and 5.81% of shares held in treasury via an ongoing buyback program initiated in June 2023.

Name

Erfo Pharmaceutical Laboratory

Legal name

Laboratorio Farmaceutico Erfo S.p.A.

Website

https://erfo.it

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Erfo Pharmaceutical Laboratory is an Italian nutraceutical manufacturer and multi-brand wellness franchisor operating a 274-point network (Diétnatural, Fit&Go, BodySano) across Italy, France, and Belgium, with proprietary supplements, a Medical Division, contract manufacturing services, and regenerative nutraceutical R&D.

Ownership category

akta.pro rank

Product category

Nutraceutical / Dietary Supplement Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411), Food (Health) Supplement Retailers (456191), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Retail-Drug Stores And Proprietary Stores (5912), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Nutraceutical manufacturing
• Dietary supplements
• Private label production
• Wellness franchising
• Medical nutraceuticals

Headquarters

HQ city

Villafranca

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations

Revenue model

1. Nutraceutical Product Sales (Retail & Franchising): Revenue from sale of proprietary nutraceutical products (70+ exclusive products) through owned retail centers, franchisee network (Diètnatural, Fit&Go, BodySano), and direct e-commerce channel. The franchise model generates both product revenue and franchise fees from the network of 274 sales points.
2. Private Label & Contract Manufacturing (Conto Terzi): Third-party manufacturing services for dietary supplements, including formulation development, production, packaging, and customization. Services include regulatory consulting, graphic design, packaging, and production of various pharmaceutical forms (bottles, vials, capsules, tablets, sachets). Over 80 formulations created for clients.
3. Medical Division Products: High scientific-value nutraceutical products commercialized through the Medical Division across therapeutic areas including andrology, gastroenterology, gynecology, neurology, dentistry, orthopedics, and vascular health. Includes products like OSTEO-THERAPY, Neuro-Therapy Brain, FerroPro Forte, and others sold via pharmacy and medical channels.
4. Franchise Fees & Network Growth: Revenue from franchise fees and network expansion activities. The company operates over 120 Diétnatural points in Italy, France, and Belgium, with expansion targeting 300 centers by 2026. Franchise network represents a core growth driver.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Core offering

Erfo Pharmaceutical Laboratory is an Italian nutraceutical manufacturer and health & wellness platform operator. The company formulates, manufactures, and packages 70+ proprietary dietary supplements, operates a 274-point franchise network of nutrition, fitness, and aesthetic centers under the Diètnatural, Fit&Go, and BodySano brands, distributes a Medical Division portfolio across seven therapeutic areas through pharmacies and healthcare professionals, and provides B2B private label/contract manufacturing (Conto Terzi) with regulatory and packaging services for third-party supplement brands.

Product overview

Erfo Pharmaceutical Laboratory is an Italian health and wellness ecosystem combining advanced research, in-house nutraceutical production, and multi-brand retail franchising. The portfolio spans three proprietary retail brands (Diètnatural, Fit&Go, and BodySano) with over 274 points of sale across Europe, the Erfo Medical Division with 18+ therapeutically-oriented nutraceutical products (Blue Performa, Alginat Plus, Butiplus Repair, Effervia, Glusan Epato Detox, Lattasi Pro, Prebiolians Immunoact, Procinetix Digestion, Transax Regolarità, Ferropro Forte, Policistix Myo-Chiro, Mind 1000, Neuro-Therapy Brain, Trianase Plus, Emorvia, Plusven Forte, Osteo-Therapy®), plus third-party contract manufacturing and private label services. The company operates ISO 9001:2015 certified production facilities with Industry 4.0 equipment and conducts R&D through collaborative projects (PLATFORM for bone regeneration, PLANTS for smart agriculture).

Differentiator

Problem solved

Functional benefit

Brands

• Diètnatural: Exclusive format combining nutraceutical supplements with a natural method for wellness and weight control. Over 120 points of sale in Italy, France, and Belgium offering free personalized nutritional consultations.
• Fit and Go
• BodySano
• Erfo Medical
• Erfo Pharma
• Osteo-Therapy®
• PLATFORM
• PLANTS

Products and services

• Diètnatural Franchise Network Exclusive franchise format combining proprietary nutraceutical supplements with a personalized wellness and weight-control method. Over 120 points of sale across Italy, France, and Belgium offering free nutritional consultations and Erfo products to individual consumers.
• Fit&Go Franchise Network High-tech fitness franchise offering rapid, complete, and intelligent training using advanced technology and qualified personal trainers. Over 120 centers across Italy.
• BodySano Franchise Network International franchise brand combining premium nutraceutical supplements with personalized nutritional coaching and advanced anti-aging aesthetic treatments, targeting French-speaking markets via Erfo France SAS.
• Produzione Conto Terzi & Private Label B2B contract manufacturing and private label services for food supplements covering every phase: research, formulation development, packaging, graphic design, regulatory consulting (Italian Ministry of Health notifications), and production in multiple pharmaceutical forms (bottles, vials, capsules, tablets, sachets). Over 80 custom formulations delivered for clients.
• Erfo Medical Division (Erfo Pharma) Medical division commercializing high-scientific-value nutraceutical products across therapeutic areas including andrology, gastroenterology, gynecology, neurology, dentistry, orthopedics, and vascular health, distributed through pharmacies and healthcare professionals.
• Osteo-Therapy® Food supplement supporting bone regeneration and osseointegration, containing Spirulina, Calcium, Vitamin D, and Quercetin. Developed within the PLATFORM research project and backed by a patent application filed December 2024 for polyphenol-based bone regeneration composition.
• Neuro-Therapy Brain Nutraceutical product for neurology support, containing tryptophan, citicoline, and bacopa, supporting memory, sleep, and relaxation. Medical Division product priced at approximately €33.
• FerroPro Forte High-bioavailability iron supplement with vitamin C, B6, B12, and folic acid for gynecology applications. Medical Division product priced at approximately €16.90.
• Plusven Forte Dietary supplement for microcirculation and heavy legs support with red vine (Vite Rossa) and centella, containing diosmin, hesperidin, blueberry, red vine, and centella. Priced at €19.90 including VAT; recommended 2 capsules daily.
• Mind 1000 Nutraceutical product for neurology applications containing carnitine, Q10, and vitamins to support mind and concentration. Medical Division product priced at approximately €26.
• Trianase Plus Compresse Tablet form nutraceutical containing boswellia, papaya, and bromelain for inflammation and natural defenses in orthopedic applications. Medical Division product priced at approximately €22.
• Blue Performa Nutraceutical product for andrology applications within the Erfo Medical Division, targeting therapeutic areas of high scientific validity.
• Emorvia Nutraceutical product for venous circulation support and hemorrhoidal plexus wellness in vascular applications.
• Policistix Myo-Chiro Nutraceutical product for gynecology applications, trademark POLICISTIX registered November 2022. Medical Division product priced at approximately €24.
• Erfo Shop E-commerce Official direct-to-consumer online store enabling purchase of all Erfo product lines including Medical Division supplements, maintaining the same quality and safety standards as franchise points.

Quantifiable outcome

• Revenue growth of 61% in 2025, reaching approximately €10 million consolidated revenues
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Consiglio Nazionale delle Ricerche (CNR)coreStrategic or Co-development Partner · 3 June 2024National research council partner in PLANTS project for smart greenhouse development and nutraceutical ingredient optimization. CNR collaborates on creating advanced monitoring and control systems for optimizing growth conditions of medicinal plants to improve quality of active ingredients for high-efficacy formulations targeting osteopenia, sarcopenia, inflammation, and oxidative stress.
• C.O.T. Cure Ortopediche Traumatologiche S.p.A.coreStrategic or Co-development Partner · 10 January 2022Lead partner in the PLATFORM research project (Accordo per l'innovazione 'Scienze della Vita'). C.O.T. provides clinical orthopedic expertise for the development of surgical planning software, personalized titanium grafts, and patient-specific cutting guides for tibial osteotomy procedures. Project aims to create an integrated platform for personalized medicine in orthopedic surgery, with Erfo contributing nutraceutical formulations for bone regeneration.
• Università Campus Bio-Medico di RomacoreStrategic or Co-development Partner · 10 January 2022Academic research partner in PLATFORM project contributing regenerative medicine expertise. UCBM focuses on advanced regenerative solutions and nanomaterial development including ceramic and glass-ceramic coatings for enhancing bioactivity of titanium bone grafts. Collaboration integrates clinical, engineering, and nutraceutical competencies for comprehensive orthopedic solutions.
• AMED - Advanced Medical Engineering Devices S.r.l.coreTechnology or Integration · 10 January 2022Technology partner providing advanced medical engineering capabilities for PLATFORM project. AMED contributes prosthetic design and development expertise for creating customized titanium medical devices integrated with implantable components (screws and plates) for orthopedic surgical procedures.
• NCS Lab S.r.l.coreTechnology or Integration · 10 January 2022Sensor technology partner in PLATFORM project developing inertial sensor grid systems for intraoperative guidance. NCS provides measurement capabilities for anatomical data collection with radio-connected graphical interface, and polymer housing suitable for sterilization and operating room use.
• Università degli Studi di MessinaminorStrategic or Co-development PartnerAcademic collaboration with University of Messina for student projects in Production, Logistics, and Marketing within the Management Engineering degree program. Students develop strategic marketing plans for new Erfo product lines, providing practical case study experience while generating innovative ideas for the company. Collaboration exemplifies Erfo's commitment to synergies between education and business.

Scale indicators10 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Pharmanutra S.p.A. Italian nutraceutical / food supplement company listed on Euronext Growth Milan, developing and commercializing proprietary supplement lines through pharmacy and medical channels - directly comparable in product category, go-to-market, and listing tier to Erfo.
• Aboca S.p.A. Italian herbal medicinal products and food supplements manufacturer with vertically integrated cultivation-to-product operations, overlapping directly with Erfo's botanical nutraceutical formulations and medical-pharmacy distribution.
• ESI S.p.A. Italian supplements and natural cosmetics company selling through pharmacy and parapharmacy channels across Europe - directly comparable category, distribution, and Italian heritage to Erfo's Medical Division.
• Named (Named Sport / Named Farma): Italian sports nutrition and dietary supplement brand sold through pharmacy channel, overlapping with Erfo's Orthomolecular / Medical Division and franchised wellness positioning.
• Sofar Farmaceutici: Italian pharmaceutical and nutraceutical manufacturer focused on urology, gynecology and specialty therapeutic areas - directly comparable on Medical Division category coverage and pharmacy distribution model.
• BioGaia AB: Public Swedish probiotic and supplement company with clinically-positioned products sold through pharmacy and healthcare professional channels - directly comparable scientifically-positioned nutraceutical model with European distribution.

Broad incumbents

• Recordati S.p.A. Large Italian specialty pharma group with significant nutraceutical / consumer health presence; broader portfolio than Erfo but overlapping on selected therapeutic franchises and pharmacy channel go-to-market.
• Menarini Group: Major Italian pharma and consumer health conglomerate with nutraceutical products distributed through pharmacy and medical channels; broader incumbent competing in the same end-markets.
• Bolton Group: Large Italian privately-held consumer health/fast-moving consumer goods group (with supplement and personal care brands); broader incumbent relevant as a benchmark for category expansion and Italian consumer health scale.

Regional players

• Farmacosmo S.p.A. Italian online pharmacy and parapharmacy e-commerce platform; comparable to Erfo's acquisition of FarmaWoW (closed October 2023) and its pharmacy-channel distribution and Erfo Shop online strategy.

Market position

Strengths5 records

Weaknesses6 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/erfospa
• LinkedInlinkedin.com/company/erfo-laboratorio-farmaceutico

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Erfo Pharmaceutical Laboratory